Progressive multifocal leukoencephalopathy in autoimmune diseases

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 351-355

  Palazzo, Elisabeth ^a   Yahia, Salim Ahmed ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Autoimmune disease; Leflunomide; Methotrexate; Progressive multifocal leukoencephalopathy; Rheumatoid arthritis; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; ETANERCEPT; GADOLINIUM; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MEFLOQUINE; METHOTREXATE; MIRTAZAPINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

AUTOIMMUNE DISEASE; BRAIN BIOPSY; CEREBROSPINAL FLUID; CHRONIC ARTHRITIS; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LOW DRUG DOSE; LUPUS VULGARIS; LYMPHOMA; MULTIPLE SCLEROSIS; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCLERODERMA; SHORT SURVEY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COMORBIDITY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; ISOXAZOLES; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; VIRUS ACTIVATION;

EID: 84863211054     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.11.002     Document Type: Short Survey

References (41)

1. Koralnik I.J., Schellingerhout D., Frosch M.P. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med 2004, 350:1882-1893.
2. Padgett B.L., Walker D.L., ZuRhein G.M., et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1:1257-1260.
3. White M.K., Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy-revisited. J Infect Dis 2011, 203:578-586.
4. Berger J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010, 33:969-983.
5. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
6. Shah R., Bag A.K., Chapman P.R., et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 2010, 65:431-439.
7. Calabrese L.H., Molloy E.S., Huang D., et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007, 56:2116-2128.
8. Tan C.S., Koralnik I.J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010, 9:425-437.
9. Tan K., Roda R., Ostrow L., et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009, 72:1458-1464.
10. Clifford D.B., Ances B., Costello C., et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011, 68:1156-1164.
11. Terrier B., Hummel A., Fakhouri F., et al. Progressive multifocal leukoencephalopathy in a non-AIDS patient: high efficiency of combined cytarabine and cidofovir. Rev Med Interne 2007, 28:488-491.
12. Marzocchetti A., Tompkins T., Clifford D.B., et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009, 73:1551-1558.
13. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009, 60:3761-3765.
14. Calabrese L.H., Molloy E.S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008, 67(Suppl. 3):iii64-iii65.
15. Warnke C., Menge T., Hartung H.P., et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?. Arch Neurol 2010, 67:923-930.
16. Clifford D.B., De Luca A., Simpson D.M., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
17. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
18. Amend K.L., Turnbull B., Foskett N., et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010, 75:1326-1332.
19. Fleischmann R.M. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60:3225-3228.
20. Molloy ES Calabrese LH. Progressive multifocal leukoencephalopathy associated with biologic and synthetic DMARD therapy in rheumatic diseases: an analysis of the FDA adverse event reporting system database [abstract]. Arthritis Rheum 2010, 62(Suppl. 10):700.
21. Kumar D., Bouldin T.W., Berger R.G. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010, 62:3191-3195.
22. Rahmlow M., Shuster E.A., Dominik J., et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008, 65:1538-1539.
23. Sponzilli E.E., Smith J.K., Malamud N., et al. Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. Neurology 1975, 25:664-668.
24. Raghavendra S., Nair M.D., Chemmanam T., et al. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol 2007, 14:309-314.
25. Renard D., Westhovens R., Vandenbussche E., et al. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004, 251:226-228.
26. Worthley S.G., McNeil J.D. Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995, 22:335-337.
27. Yokoo H., Nakazato Y., Harigaya Y., et al. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. Acta Neuropathol 2007, 114:425-430.
28. Boren E.J., Cheema G.S., Naguwa S.M., et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008, 30:90-98.
29. Khatri B.O., Man S., Giovannoni G., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009, 72:402-409.
30. Carson K.R., Bennett C.L. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009, 50:323-324.
31. Martin M., del Pilar, Cravens P.D., et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009, 66:1016-1020.
32. Chapagain M.L., Nerurkar V.R. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010, 202:184-191.
33. Govindappa V., Hicks S., Wichter M., et al. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus. Arthritis Rheum 2007, 57:352-354.
34. Shprecher D., Frech T., Chin S., et al. Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus 2008, 17:1029-1032.
35. Harris H.E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008, 47:224-225.
36. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 2008, 8:144-146.
37. Lefevre G., Queyrel V., Maurage C.A., et al. Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. J Neurol Sci 2009, 287:246-249.
38. Pagnoux C., Hayem G., Roux F., et al. JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine 2003, 70:376-379.
39. Terrier B., Martinez V., Seilhean D., et al. Progressive multifocal leukoencephalopathy mimicking cerebral vasculitis in systemic granulomatosis. J Infect 2007, 54:e133-e135.
40. Vulliemoz S., Lurati-Ruiz F., Borruat F.X., et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006, 77:1079-1082.
41. Hayashi Y., Kimura A., Kato S., et al. Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjogren syndrome. J Neurol Sci 2008, 268:195-198.